Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib in Refractory Renal Cell Carcinoma
NCT01775930Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2013
- Primary completion
- Jan 2019
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01775930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01775930.